IMF Virtual Regional Community Workshop (RCW) - Pacific Northwest

Virtual Multiple Myeloma Community Workshop 

A virtual multiple myeloma workshop addressing the needs specific to communities in the Pacific Northwest Region of the United States.

The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy, relapse information, and an update on clinical trials. A member of the IMF Nurse Leadership Board will talk about managing side effects and symptoms of myeloma and its treatments. After each presentation with the experts, attendees will have ample time to ask questions.



RCW Pacific Northwest 2022 Speaker Headshots


Welcome and Announcements

Kelly Cox, Senior Director IMF Regional Community Workshops

Myeloma 101 and Frontline Therapy

Craig Cole, MD (Michigan State University-Karmanos Cancer Institute, Detroit, MI) reviews multiple myeloma basics including what myeloma is, common symptoms and side effects, advances in how myeloma is initially diagnosed, the stages of myeloma treatment, induction therapy, transplant, and more. 

Relapsed Therapy and Clinical Trials

Amrita Krishnan, MD (City of Hope Comprehensive Cancer Center, Duarte, CA) discusses the types of relapsed disease, what doctors consider when selecting a treatment regimen, relapsed/refractory treatment options, how doctors treat triple and penta-class refractory myeloma, updates on clinical trials, and more. 

Managing Multiple Myeloma symptoms and treatment side effects

Sandra Rome, RN, MN, AOCN, CNS (Cedars-Sinai Medical Center, Los Angeles, CA, IMF Nurse Leadership Board) discusses how patients can manage myeloma-related symptoms and side effects along with side effects brought on by treatment. She outlines the most common side effects for each myeloma drug category, how to prevent infection, and more.

Additional Resources:

Download the IMF's Multiple Myeloma Informational Booklets:

Download IMF publications


What Is a Clinical Trial?

*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:

Workshop Sponsors:

With Support From: Amgen, Bristol Myers Squibb, GSK, Janssen, Karyopharm, and Takeda Oncology

(The IMF is not responsible for content provided by the links below and you may be subject to the Privacy Policy and Terms & Conditions of the destination site(s).)


Even the Odds

Revlimid Treatment Overview brochure

Pomalyst Transition Treatment brochure

Harness your power to fight MM with ABECMA®

DARZALEX® Patient Website

DARZALEX FASPRO™ Patient Brochure

DARZALEX FASPRO™ Dosing Calendar


Learn About XPOVIO® (selinexor)

See If XPOVIO Could Be Right For You

Get XPOVIO Patient Support


Takeda Oncology

English Lab Test Tracker

Conquering Myeloma Compendium MAT-USO-NON-19-00020

CONQUER the Patient voice – Real World Evidence


Closed Captions Available

IMF TV Blog Category

Source URL: